OTC Drug-Supplement Combo Products Now Caught in Regulatory Quagmire

FDA’s recent warning to Bayer leaves industry divided as to how to pursue opportunity and could signal new regulatory stance for supplements

The products have all the right stuff to rise to blockbuster status: They are backed by solid science; they meet a consumer need and provide convenience; and they carry a strong marketing message. Yet, all bets on products made with over-the-counter (OTC) drugs and dietary supplement ingredients are currently pending, following the recent warning letters the U.S. Food and Drug Administration (FDA) sent to pharmaceutical giant Bayer regarding its Bayer Aspirin with Heart

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.